Notice of Availability of Environmental Assessment and Finding of No Significant Impact for License Amendment for Purdue Pharma, L.P.'s Facility in Cranbury, NJ, 59779-59780 [E5-5597]

Download as PDF Federal Register / Vol. 70, No. 197 / Thursday, October 13, 2005 / Notices 6, Memorial Drive and Wadsworth Street, Cambridge, MA. Status: This workshop will be open to the public. Engineering Workforce Issues and Engineering Education: What Are the Linkages? 8:25 a.m. Welcome Warren M. Washington,* Chairman, National Science Board 8:30 a.m. Panel 1: Aspirations for Engineering Education Opening Remarks—Daniel Hastings,* National Science Board National Academy of Engineering— The Engineer of 2020, Phases I & II G. Wayne Clough,* National Science Board Data, trends, and outlooks—John A. Brighton,* Iowa State University NSF activities in engineering—Arden L. Bement,* National Science Foundation 9:10 a.m. Group Discussion among Workshop Participants 9:20 a.m. Questions and Comments from the Audience 9:30 a.m. Panel 2: Engineering Education—Present and Future Moderator: Daniel Hastings, National Science Board Alice Agogino,* University of California, Berkeley; Richard Miller,* Olin College of Engineering; Linda Katehi,* Purdue University; Eli Fromm,* Drexel University; and Tom Magnanti,* MIT. 10:30 a.m. Group Discussion among Workshop Participants 11:15 a.m. Questions and Comments from the Audience 11:30 a.m. Break 1 p.m. Panel 3: Engineering Employment—Present and Future Moderator: Louis L. Lanzerotti, National Science Board Peter Pao;* Raytheon Company; Ronil Hira,* IEEE–USA; Jim Miller,* Cisco Systems, Inc.; and Gloria Jeff,* Michigan Department of Transportation. 2 p.m. Group Discussion among Workshop Participants 2:45 p.m. Questions and Comments from the Audience 3 p.m. Breakout Sessions to Address the Question: How do we ensure that the best and the brightest students pursue engineering studies and careers, and that their education quality, content, and teaching are of the highest caliber? Location: Dining 3, Dining 5, and Dining 6 Session Chairs: G. Wayne Clough, Louis L. Lanzerotti, Daniel Hastings 4:30 p.m. Report Out and Wrap-Up VerDate Aug<31>2005 16:14 Oct 12, 2005 Jkt 208001 Moderator: Daniel Hastings* *Confirmed speaker For Further Information Contact: Dr. Michael P. Crosby, Executive Officer and NSB Office Director, (703) 292– 7000, http://www.nsf.gov/nsb. Michael P. Crosby, Executive Officer and NSB Office Director. [FR Doc. 05–20554 Filed 10–12–05; 8:45 am] BILLING CODE 7555–01–P NATIONAL SCIENCE FOUNDATION Sunshine Act; President’s Committee on the National Medal of Science; Notice of Meeting In accordance with the Federal Advisory Committee Act (Pub. L. 92– 463, as amended), the National Science Foundation announces the following meeting: President’s Committee on the National Medal of Science (1182). NAME: Tuesday, October 25, 2005, 8:30 a.m.–1:30 p.m. DATE AND TIME: Room 555–II, National Science Foundation, 4201 Wilson Blvd, Arlington, VA. PLACE: TYPE OF MEETING: Closed. Ms. Ann Noonan, Honorary Awards Specialist, Room 1220, National Science Foundation, 4201 Wilson Blvd, Arlington, VA 22230. Telephone: 703–292–8096. CONTACT PERSON: To provide advice and recommendations to the President in the selection of the 2005 National Medal of Science recipients. PURPOSE OF MEETING: To review and evaluate nominations as part of the selection process for awards. AGENDA: The nominations being reviewed include information of a personal nature where disclosure would constitute unwarranted invasions of personal privacy. These matters are exempt under 5 U.S.C. 552b(c)(6) of the Government in the Sunshine Act. REASON FOR CLOSING: Dated: October 11, 2005. Susanne Bolton, Committee Management Officer. [FR Doc. 05–20648 Filed 10–11–05; 3:47 pm] BILLING CODE 7555–01–M PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 59779 NUCLEAR REGULATORY COMMISSION [Docket No. 030–35882] Notice of Availability of Environmental Assessment and Finding of No Significant Impact for License Amendment for Purdue Pharma, L.P.’s Facility in Cranbury, NJ Nuclear Regulatory Commission. ACTION: Notice of availability. AGENCY: FOR FURTHER INFORMATION CONTACT: Betsy Ullrich, Commercial and R&D Branch, Division of Nuclear Materials Safety, Region I, 475 Allendale Road, King of Prussia, Pennsylvania 19406, telephone (610) 337–5040, fax (610) 337–5269; or by e-mail: exu@nrc.gov. SUPPLEMENTARY INFORMATION: I. Introduction The Nuclear Regulatory Commission (NRC) is considering issuing a license amendment to Purdue Pharma, L.P. for Materials License No. 29–30698–01, to authorize release of its facility in Edgewater, New Jersey, for unrestricted use. NRC has prepared an Environmental Assessment (EA) in support of this action in accordance with the requirements of 10 CFR part 51. Based on the EA, the NRC has concluded that a Finding of No Significant Impact (FONSI) is appropriate. II. EA Summary The purpose of the proposed action is to authorize the release of two sections of the licensee’s Cranbury, New Jersey, facility for unrestricted use. Purdue Pharma, L.P. was authorized by NRC from 2002 to use radioactive materials for research and development purposes at the site. On April 21, 2005, Purdue Pharma, L.P. requested that NRC release two sections of the facility for unrestricted use. Purdue Pharma, L.P. has conducted surveys of the two sections of the facility and provided information to the NRC to demonstrate that the site meets the license termination criteria in subpart E of 10 CFR part 20 for unrestricted use. The NRC staff has prepared an EA in support of the license amendment. The two sections of the facility were remediated and surveyed prior to the licensee requesting the license amendment. The NRC staff has reviewed the information and final status survey submitted by Purdue Pharma, L.P. Based on its review, the staff has determined that there are no additional remediation activities E:\FR\FM\13OCN1.SGM 13OCN1 59780 Federal Register / Vol. 70, No. 197 / Thursday, October 13, 2005 / Notices necessary to complete the proposed action. Therefore, the staff considered the impact of the residual radioactivity at the facility and concluded that since the residual radioactivity meets the requirements in subpart E of 10 CFR part 20, a Finding of No Significant Impact is appropriate. III. Finding of No Significant Impact The staff has prepared the EA (summarized above) in support of the license amendment to terminate the license and release the facility for unrestricted use. The NRC staff has evaluated Purdue Pharma, L.P.’s request and the results of the surveys and has concluded that the completed action complies with the criteria in Subpart E of 10 CFR part 20. The staff has found that the radiological environmental impacts from the action are bounded by the impacts evaluated by NUREG–1496, Volumes 1–3, ‘‘Generic Environmental Impact Statement in Support of Rulemaking on Radiological Criteria for License Termination of NRC-Licensed Facilities’’ (ML042310492, ML042320379, and ML042330385). Additionally, no non-radiological or cumulative impacts were identified. On the basis of the EA, the NRC has concluded that the environmental impacts from the action are expected to be insignificant and has determined not to prepare an environmental impact statement for the action. IV. Further Information Documents related to this action, including the application for the license amendment and supporting documentation, are available electronically at the NRC’s Electronic Reading Room at http://www.nrc.gov/ reading-rm/adams.html. From this site, you can access the NRC’s Agencywide Document Access and Management System (ADAMS), which provides text and image files of NRC’s public documents. The ADAMS accession numbers for the documents related to this Notice are: Environmental Assessment Related to an Amendment of U.S. Nuclear Regulatory Commission Materials License No. 29–30698–01, Issued to Purdue Pharma, L.P. (ML052780150), the Purdue Pharma, L.P. letter dated April 21, 2005 (ML052590192) and the Purdue Pharma, L.P. letter dated June 30, 2005 (ML052590186). Persons who do not have access to ADAMS or who encounter problems in accessing the documents located in ADAMS, should contact the NRC PDR Reference staff by telephone at (800) 397–4209 or (301) 415–4737, or by e-mail to pdr@nrc.gov. VerDate Aug<31>2005 16:14 Oct 12, 2005 Jkt 208001 Documents related to operations conducted under this license not specifically referenced in this Notice may not be electronically available and/ or may not be publicly available. Persons who have an interest in reviewing these documents should submit a request to NRC under the Freedom of Information Act (FOIA). Instructions for submitting a FOIA request can be found on the NRC’s Web site at http://www.nrc.gov/reading-rm/ foia/foia-privacy.html. Dated at King of Prussia, Pennsylvania, this 5th of October, 2005. For the Nuclear Regulatory Commission. James P. Dwyer, Chief, Commercial and R&D Branch, Division of Nuclear Materials Safety, Region I. [FR Doc. E5–5597 Filed 10–12–05; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION Advisory Committee on Nuclear Waste Meeting on Planning and Procedures; Notice of Meeting The Advisory Committee on Nuclear Waste (ACNW) will hold a Planning and Procedures meeting on October 20, 2005, in the Fairway Room at the Inn at Holiday Valley, 6081 Route 219, Holiday Valley Road, Ellicottville, New York. The entire meeting will be open to public attendance, with the exception of a portion that may be closed pursuant to 5 U.S.C. 552b(c)(2) and (6) to discuss organizational and personnel matters that relate solely to internal personnel rules and practices of ACNW, and information the release of which would constitute a clearly unwarranted invasion of personal privacy. The agenda for the subject meeting shall be as follows: Thursday, October 20, 2005, 8 a.m.– 9:30 a.m. The Committee will discuss proposed ACNW activities and related matters. The purpose of this meeting is to gather information, analyze relevant issues and facts, and formulate proposed positions and actions, as appropriate, for deliberation by the full Committee. Members of the public desiring to provide oral statements and/or written comments should notify the Designated Federal Official, Ms. Sharon A. Steele (Telephone: (301) 415–6805) between 8:30 a.m. and 5:15 p.m. (ET) five days prior to the meeting, if possible, so that appropriate arrangements can be made. Electronic recordings will be permitted only during those portions of the meeting that are open to the public. PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 Further information regarding this meeting can be obtained by contacting the Designated Federal Official between 8:30 a.m. and 5:15 p.m. (ET). Persons planning to attend this meeting are urged to contact the above named individual at least two working days prior to the meeting to be advised of any potential changes in the agenda. Dated: October 6, 2005. Michael L. Scott, Branch Chief, ACRS/ACNW. [FR Doc. E5–5595 Filed 10–12–05; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION Advisory Committee on Nuclear Waste; Notice of Meeting The Advisory Committee on Nuclear Waste (ACNW) will hold its 164th meeting on October 19–20, 2005, in the Fairway Room at the Inn at Holiday Valley, 6081 Route 219, Holiday Valley Road, Ellicottville, New York. The schedule for this meeting is as follows: Wednesday, October 19, 2005 The ACNW will hold a working group meeting to discuss the application of the Commission’s Final Policy Statement on Decommissioning Criteria for the West Valley Demonstration Project (WVDP) a complex decommissioning site. Participants will include the Nuclear Regulatory Commission (NRC) staff, the Department of Energy (DOE), the New York State Energy Research and Development Authority (NYSERDA), as well as other federal and state organizations and local stakeholders. 8:30 a.m.–8:45 a.m.: Introduction, Purpose and Goals (Open)—The Committee’s Chairman and Working Group Chairman will discuss the purpose and goals of this working group meeting. 8:45 a.m.–9:15 a.m.: Roles and Responsibilities (Open)—The Committee will hear presentations by and hold discussions with representatives of involved agencies (NRC, DOE, NYSERDA and others) regarding their roles and responsibilities in the WVDP. Additionally, the NRC staff will discuss the WVDP Act and NRC’s Final Policy Statement on the Decommissioning Criteria for the WVDP. 9:15 a.m.–10:30 a.m.: NRC’s Performance Assessment Methodology (Open)—The Committee will hear presentations by and hold discussions with representatives of the NRC staff on models and methodology used in their E:\FR\FM\13OCN1.SGM 13OCN1

Agencies

[Federal Register Volume 70, Number 197 (Thursday, October 13, 2005)]
[Notices]
[Pages 59779-59780]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-5597]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 030-35882]


Notice of Availability of Environmental Assessment and Finding of 
No Significant Impact for License Amendment for Purdue Pharma, L.P.'s 
Facility in Cranbury, NJ

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of availability.

-----------------------------------------------------------------------

FOR FURTHER INFORMATION CONTACT: Betsy Ullrich, Commercial and R&D 
Branch, Division of Nuclear Materials Safety, Region I, 475 Allendale 
Road, King of Prussia, Pennsylvania 19406, telephone (610) 337-5040, 
fax (610) 337-5269; or by e-mail: exu@nrc.gov.

SUPPLEMENTARY INFORMATION:

I. Introduction

    The Nuclear Regulatory Commission (NRC) is considering issuing a 
license amendment to Purdue Pharma, L.P. for Materials License No. 29-
30698-01, to authorize release of its facility in Edgewater, New 
Jersey, for unrestricted use. NRC has prepared an Environmental 
Assessment (EA) in support of this action in accordance with the 
requirements of 10 CFR part 51. Based on the EA, the NRC has concluded 
that a Finding of No Significant Impact (FONSI) is appropriate.

II. EA Summary

    The purpose of the proposed action is to authorize the release of 
two sections of the licensee's Cranbury, New Jersey, facility for 
unrestricted use. Purdue Pharma, L.P. was authorized by NRC from 2002 
to use radioactive materials for research and development purposes at 
the site. On April 21, 2005, Purdue Pharma, L.P. requested that NRC 
release two sections of the facility for unrestricted use. Purdue 
Pharma, L.P. has conducted surveys of the two sections of the facility 
and provided information to the NRC to demonstrate that the site meets 
the license termination criteria in subpart E of 10 CFR part 20 for 
unrestricted use.
    The NRC staff has prepared an EA in support of the license 
amendment. The two sections of the facility were remediated and 
surveyed prior to the licensee requesting the license amendment. The 
NRC staff has reviewed the information and final status survey 
submitted by Purdue Pharma, L.P. Based on its review, the staff has 
determined that there are no additional remediation activities

[[Page 59780]]

necessary to complete the proposed action. Therefore, the staff 
considered the impact of the residual radioactivity at the facility and 
concluded that since the residual radioactivity meets the requirements 
in subpart E of 10 CFR part 20, a Finding of No Significant Impact is 
appropriate.

III. Finding of No Significant Impact

    The staff has prepared the EA (summarized above) in support of the 
license amendment to terminate the license and release the facility for 
unrestricted use. The NRC staff has evaluated Purdue Pharma, L.P.'s 
request and the results of the surveys and has concluded that the 
completed action complies with the criteria in Subpart E of 10 CFR part 
20. The staff has found that the radiological environmental impacts 
from the action are bounded by the impacts evaluated by NUREG-1496, 
Volumes 1-3, ``Generic Environmental Impact Statement in Support of 
Rulemaking on Radiological Criteria for License Termination of NRC-
Licensed Facilities'' (ML042310492, ML042320379, and ML042330385). 
Additionally, no non-radiological or cumulative impacts were 
identified. On the basis of the EA, the NRC has concluded that the 
environmental impacts from the action are expected to be insignificant 
and has determined not to prepare an environmental impact statement for 
the action.

IV. Further Information

    Documents related to this action, including the application for the 
license amendment and supporting documentation, are available 
electronically at the NRC's Electronic Reading Room at http://
www.nrc.gov/reading-rm/adams.html. From this site, you can access the 
NRC's Agencywide Document Access and Management System (ADAMS), which 
provides text and image files of NRC's public documents. The ADAMS 
accession numbers for the documents related to this Notice are: 
Environmental Assessment Related to an Amendment of U.S. Nuclear 
Regulatory Commission Materials License No. 29-30698-01, Issued to 
Purdue Pharma, L.P. (ML052780150), the Purdue Pharma, L.P. letter dated 
April 21, 2005 (ML052590192) and the Purdue Pharma, L.P. letter dated 
June 30, 2005 (ML052590186). Persons who do not have access to ADAMS or 
who encounter problems in accessing the documents located in ADAMS, 
should contact the NRC PDR Reference staff by telephone at (800) 397-
4209 or (301) 415-4737, or by e-mail to pdr@nrc.gov.
    Documents related to operations conducted under this license not 
specifically referenced in this Notice may not be electronically 
available and/or may not be publicly available. Persons who have an 
interest in reviewing these documents should submit a request to NRC 
under the Freedom of Information Act (FOIA). Instructions for 
submitting a FOIA request can be found on the NRC's Web site at http://
www.nrc.gov/reading-rm/foia/foia-privacy.html.

    Dated at King of Prussia, Pennsylvania, this 5th of October, 
2005.

    For the Nuclear Regulatory Commission.
James P. Dwyer,
Chief, Commercial and R&D Branch, Division of Nuclear Materials Safety, 
Region I.
 [FR Doc. E5-5597 Filed 10-12-05; 8:45 am]
BILLING CODE 7590-01-P